Position in ADCT
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$82,476
-$187,827 QoQ
Shares Held
77,081
+6.9% QoQ
Ownership
0.060%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#47
of 113 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ADCT Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026DAFNA Capital Management LLC holds $22,367,669 across 6 Drug Manufacturers - Specialty & Generic names. ADCT ranks #6 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
57,769 | $9,736,387 | |
| 2 | ALKS |
Alkermes plc.
|
101,266 | $5,306,338 | |
| 3 | BCRX |
Biocryst Pharmaceuticals Inc
|
400,248 | $4,002,480 | |
| 4 | AQST |
Aquestive Therapeutics, Inc.
|
645,915 | $2,687,006 | |
| 5 | SCYX |
Scynexis Inc
|
135,868 | $552,982 | |
| 6 | ADCT |
ADC Therapeutics SA
This page
|
77,081 | $82,476 |
All Filings in ADCT
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $82,476 | 77,081 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $270,303 | 72,081 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $272,095 | 77,081 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $488,324 | 122,081 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $327,177 | 122,081 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $315,954 | 224,081 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $445,921 | 224,081 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $642,855 | 204,081 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $644,895 | 204,081 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||